News

Potassium Targets for Acute MI Too High, Outdated

View on the News

Higher Potassium Targets ‘Not Justified’

Potassium repletion to levels higher than 4.5 mEq/L no longer appear to be justified in acute MI, said Dr. Benjamin M. Scirica and Dr. David A. Morrow.

Even potassium levels of 4.0-4.5 mEq/L were associated with increased mortality, compared with levels of 3.5-4.0 mEq/L, and 43% of all the patients in this study fell into that category.

However, it is reasonable to avoid significant hypokalemia (less than 3.5 mEq/L), especially for patients who have significant, sustained, ventricular ectopy or other high-risk features.

Dr. Scirica and Dr. Morrow are at the Levine Cardiac Unit at Brigham and Women’s Hospital and Harvard Medical School, both in Boston. They reported numerous ties to pharmaceutical companies. These remarks were adapted from their editorial comment accompanying Dr. Goyal’s report (JAMA 2012;307:195-6).


 

FROM JAMA

Current guidelines for correcting serum potassium levels in patients who present with acute MI are out of date and aim for targets that are too high, raising the risk of in-hospital mortality, according to a report in the Jan. 11 issue of JAMA.

In a retrospective study of 38,689 cases of MI in a nationally representative database, there was a U-shaped relationship between serum potassium level at admission an in-hospital mortality. The lowest mortality occurred in patients with potassium levels of 3.5-4.5 mEq/L, with higher mortality in those with potassium levels of 4.5 mEq/L or higher as well as those with levels less than 3.5 mEq/L.

Current practice guidelines recommend raising "low" potassium to 4.0-5.0 mEq/L, "and some experts even advise a higher range of 4.5-5.5 mEq/L," said Dr. Abhinav Goyal of the schools of medicine and public health at Emory University, Atlanta, and his associates.

"These guidelines are based on small, older studies that focused only on [preventing] ventricular arrhythmias (and not mortality) and were conducted before the routine use of beta-blockers, reperfusion therapy, and early invasive management in acute MI patients. Our data suggest that ... potassium levels of greater than 4.5 mEq/L are associated with increased mortality and probably should be avoided," they noted.

Dr. Goyal and his colleagues performed their study because measuring and repleting potassium to prevent arrhythmia in patients who present with acute MI is an entrenched practice, despite "the lack of current, adequately powered studies that define the optimal range of serum potassium levels with respect to mortality and other important clinical outcomes." They used information from the Cerner Corporation’s Health Facts database, which covers nearly 400,000 consecutive MI patients who presented to 67 U.S. hospitals representing all geographic regions of the country in 2000-2008.

A total of 2,679 of these study subjects (6.9%) died during hospitalization.

Compared with the reference group (potassium level of 3.5-4.0 mEq/L), in which in-hospital mortality was 4.8%, patients with levels of 4.0-4.5 had comparable mortality (5.0%).

In contrast, mortality was twice as great (10.0%) for patients with potassium levels of 4.5-5.0 mEq/L, and was even greater at higher levels, the investigators said (JAMA 2012;307:157-64).

"Our findings suggest that overly aggressive repletion of potassium levels (which is often automated through the implementation of hospital order sets) may not be advisable in patients with acute MI ... as potassium levels of at least 4.5 mEq/L are associated with harm," they noted.

As expected, mortality also was greater for patients with low potassium levels below 3.5 mEq/L.

These associations persisted in further analyses that adjusted for potentially confounding factors such as patient age, sex, and glomerular filtration rate at admission. They also remained robust regardless of whether patients did or did not receive potassium supplementation during hospitalization, and remained robust when the analysis was restricted only to patients who survived past the first 24 hours.

The investigators cautioned that their findings apply only to patients with acute MI and should not be extrapolated to those with other cardiac conditions, including heart failure.

This study was supported in part by Saint Luke’s Mid America Heart Institute, Kansas City, Mo. No conflicts of interest were reported.

Recommended Reading

Analyses Find Calcium Plus Vitamin D Increases MI Risk
MDedge Family Medicine
High Platelet Reactivity Signals High Risk of Ischemic Events
MDedge Family Medicine
Empowering Patients: Do They REALLY Know What DNR Means?
MDedge Family Medicine
Defensive Medicine Factors Into Cardiac Admissions
MDedge Family Medicine
Triple Therapy With Vorapaxar Fails in ACS
MDedge Family Medicine
Free Meds Boost Post-MI Outcomes, Rx Adherence
MDedge Family Medicine
Urinary Sodium Excretion Levels Flag CV Risk
MDedge Family Medicine
Undiagnosed Diabetes Common in Women With Acute MI
MDedge Family Medicine
ADHD Medications Found Not to Raise Risk of Serious CVD Events
MDedge Family Medicine
Dabigatran Tied to Increase in Heart Attack Risk
MDedge Family Medicine